OSAKA, Japan & CAMBRIDGE, Mass. - Monday, 30. March 2026 AETOSWire Print
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies
A significantly greater PASI 75 response rate versus placebo was observed as early as week 4
Safety profile consistent with Phase 2b studies with no new safety signals identified
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2
“Our goal in psoriasis treatment is clear or almost cle
...
Read more »
